Anavex Life Sciences’ Blarcamesine: A Once Daily Oral Alzheimer’s Disease Medication
In a groundbreaking development, Anavex Life Sciences has released key findings from its ANAVEX2-73-AD-004 trial, which evaluated the efficacy and safety of Anavex’s blarcamesine, an oral medication for the treatment of early Alzheimer’s disease (AD). The Phase IIb/III randomized double-blind, placebo-controlled study enrolled 508 participants across 52 medical research centers in five countries. The trial […]